JRCT ID: jRCT2031220487
Registered date:04/12/2022
Special Use-results Survery of Rituxan Intravenous Injection - Relapse Prevention of Neuromyelitis Optica Spectrum Disorder (including Neuromyelitis Optica) -
Basic Information
Recruitment status | Recruiting |
---|---|
Health condition(s) or Problem(s) studied | neuromyelitis optica spectrum disorder (including neuromyelitis optica) |
Date of first enrollment | 04/12/2022 |
Target sample size | 200 |
Countries of recruitment | |
Study type | Observational |
Intervention(s) |
Outcome(s)
Primary Outcome | Incidence of adverse drug reactions and severe adverse events (including grade 3/4 laboratory abnormalities) |
---|---|
Secondary Outcome |
Key inclusion & exclusion criteria
Age minimum | Not applicable |
---|---|
Age maximum | Not applicable |
Gender | Both |
Include criteria | Patients who have received Rituxan intravenous injection for relapse prevention of neuromyelitis optica spectrum disorder (including neuromyelitis optica) |
Exclude criteria | none |
Related Information
Primary Sponsor | Ando Takashi |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | |
Secondary ID(s) |
Contact
Public contact | |
Name | Junko Sakamoto |
Address | 6-15, Otsuka 5-chome, Bunkyo-ku, Tokyo Tokyo Japan 112-8650 |
Telephone | +81-339461136 |
Junko_Sakamoto@mail.zenyaku.co.jp | |
Affiliation | Zenyaku Kogyo, Co., LTD. |
Scientific contact | |
Name | Takashi Ando |
Address | 6-15, Otsuka 5-chome, Bunkyo-ku, Tokyo Tokyo Japan 112-8650 |
Telephone | +81-339461136 |
Takashi_Ando@mail.zenyaku.co.jp | |
Affiliation | Zenyaku Kogyo, Co., LTD. |